Hypersensitivity to the components of the formula; elderly or children under 12-16 years; patients with pulmonary hypertension or severe hypertension; history of cardiovascular or cerebrovascular enf;
psychiatric disorders, including anorexia nervosa and depression; history or predisposition to drug and alcohol use; advanced atherosclerosis; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; prostatic hypertrophy or any obstructive condition of the urinary tract; closed angle glaucoma; states of agitation; Do not use concomitantly with other centrally acting anorexigenics, due to the increased risk of pulmonary hypertension from life-threatening consequences, or with antidepressants or MAOIs, it should not be administered within 15 days of taking an MAOI due to the risk of presenting hypertensive crisis.
Warnings and precautions
Strict medical control; Before prescribing clobenzorex, secondary organic causes of obesity should be excluded; include dietary and psychotherapeutic measures; risk of severe pulmonary hypertension, so the therapeutic indications and duration of treatment should be respected, a treatment greater than 3 months and a BMI = 30 kg / m2 increases the risk of pulmonary hypertension, appearance or aggravation of dyspnea on the breath suggests possibility of pulmonary hypertension occurring so the treatment should be stopped immediately and the patient go to a specialized center; cardiovascular and cerebrovascular accidents, often after rapid weight loss. In obese patients at risk of enf. vascular care should be taken to ensure gradual and controlled weight loss; patients with a history of enf. cerebrovascular or cardiovascular; sympathomimetic amines lose anorexigenic power after several weeks of tto; Prolonged treatment may cause dependence with withdrawal syndrome when withdrawal. and severe psychotic disorders in patients with predisposition; epileptic patients; do not interrupt the tto abruptly, unless it is because of some R. Adv.
Adm. 15 days after interrupting a treatment with an MAOI, hypertensive crises could occur; tricyclic antidepressants and serotonin reuptake inhibitors such as venlafaxine and citalopram by increasing the risk of presenting serotonergic syndrome; guanetidine or its derivatives by sharing the same place of action and guanetidine and its derivatives could be displaced by decreasing their antihypertensive effect; Phenylethylamine derivatives, appetite suppressants such as sibutramine and tricyclic antidepressants, as it may potentiate the effects on blood pressure of the latter; Sympathomimetic and anesthetic agents in general can cause arrhythmias.
Lab: positive reaction in antidoping tests
Insufficient clinical experience.
Given the insufficient clinical experience its use is not recommended
Clobenzorex adverse reactions
Pulmonary hypertension; drug tolerance, dependence and withdrawal syndrome; psychotic reactions or psychosis, depression, nervousness, agitation, sleep disorders and vertigo; tachycardia, palpitations, high blood pressure and chest pain; dry mouth and constipation; dysuria and urinary retention